OncLive TV

Laura Dawson, MD, Princess Margaret Hospital, University of Toronto, talks about the challenges in treating hepatocellular carcinoma (HCC).

Joseph Alvarnas, MD, the director of Medical Quality at City of Hope National Medical Center, discusses autologous hematopoietic stem cell transplantation (AHCT) for patients with HIV-associated lymphoma.

Andre Goy, MD, MS chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the impact of Roche's recent acquisition of the molecular testing company Foundation Medicine.

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses remaining questions regarding immunotherapies for the treatment of melanoma.

No one biomarker is effective for all types of bladder cancer, says Michael Cookson, MD, a professor and chairman of the Department of Urology at the University of Oklahoma College of Medicine.

Anjali Advani, MD ,staff physician, Department of Hematologic Oncology and Blood Disorders, Director, Inpatient Leukemia Program, Taussig Cancer Institute, associate professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, compares inotuzumab ozogamicin, a CD22 monoclonal antibody, to blinatumomab, a CD19 bi-specific anti-CD19/CD3 antibody for the treatment of acute lymphoblastic leukemia (ALL).

Paul Sieber, MD, principal investigator for clinical trials with Lancaster Urology, talks about the CHAARTED trial, which examines chemohormonal therapy versus androgen ablation for extensive disease in prostate cancer.

Richard Fisher, MD, president and CEO of Fox Chase Cancer Center, discusses adding bortezomib (Velcade) to the standard R-CHOP regiment (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) for previously untreated mantle cell lymphoma.

Carlos Arteaga, MD, assistant director, Clinical Research, director, Breast Cancer program, Vanderbilt-Ingram Cancer Center, discusses the PI3K pathway and the role of therapeutic inhibitors in reducing the progression of breast cancer.

Corey Langer, MD, the director of Thoracic Oncology at the University of Pennsylvania, discuses afatinib, which was approved in 2013 for first line EGFR-mutated advanced non-small cell lung cancer.

Gareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses his expectations of multiple myeloma treatment going forward.

Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center at San Antonio, discusses a recent clinical trial that looks at the combination of two chemotherapy drugs, carboplatin and eribulin, along with the PARP inhibitor E7449 for the treatment of breast and ovarian cancer.

Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the use of monoclonal antibodies for the treatment of multiple myeloma.

Leonard Gomella, MD, urology specialist from Jefferson University, talks about the challenge of treating prostate cancer patients with a Gleason score of less than six.

Shaji Kumar, MD, professor of medicine at the Mayo Clinic, discusses the use of the proteasome inhibitor ixazomib in combination with lenalidomide (Revlimid) and dexamethasone for the treatment of newly diagnosed multiple myeloma.

Naoto Tada Ueno, MD, PhD, FACP, from The University of Texas MD Anderson Cancer Center, discusses the advantages of liquid biopsy to detect and monitor tumor growth.

Beth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, speaks on treatment challenges of inflammatory breast cancer.

Lisa A. Carey, MD, the Division Chief of Hematology and Oncology at the University of North Carolina and the Physician-in-Chief at North Carolina Cancer Hospital, discusses triple-negative breast cancer (TNBC) and the importance of understanding how it differs from other types of breast cancer.

David Spigel, MD, director, Lung Cancer Research Program, Sarah Cannon Research Institute, discusses the development of onartuzumab for the treatment of patients with lung cancer.

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the efficacy and safety of the combination of idelalisib and rituximab for older patients with chronic lymphocytic leukemia.

Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses the molecular biology of ovarian cancer.

Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses exciting new therapies for lymphomas and chronic lymphocytic leukemia (CLL).

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses recent updates in bladder cancer treatment.

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the future of prostate cancer research.

Randall F. Holcombe, MD, professor, Chief Medical Officer, Cancer, Mount Sinai Health System, discusses key takeaways for a practicing oncologist regarding the stool DNA test for colon cancer.

Andre Goy, MD, MS, discusses intensive therapy for the treatment of patients with mantle cell lymphoma (MCL).

Enriqueta Felip, MD, PhD, medical oncologist, Vall d'Hebron University Hospital, Barcelona, Spain, discusses the efficacy and safety of ceritinib in patients with ALK-positive non-small cell lung cancer (NSCLC).

Quincy Chu, MD, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, discusses the ability of ceritinib to penetrate the CNS.